社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
港股多模态
IP属地:未知
+关注
帖子 · 43
帖子 · 43
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
港股多模态
港股多模态
·
09-07 15:56
中国水发(00750.HK)估值严重被低估,2025年及2026年中期扭亏为盈
$水发兴业能源(00750)$
$恒生指数(HSI)$
数据来源:真灼财经综合公司年报、2026年中期业绩公告及情景模型测算制图
看
257
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
中国水发(00750.HK)估值严重被低估,2025年及2026年中期扭亏为盈
港股多模态
港股多模态
·
08-31
净利大增75%+上市以来首次派息,西普尼 (02583.HK) 中报含金量几何?
黄金消费行业从来不缺热度,但对一家企业而言,金价上涨、市场关注度提升,并不必然转化为经营质量的改善。原材料价格上行可能推高产品售价,也可能抑制终端需求;消费者对黄金的关注度提升,可以带动行业景气,却未必能够帮助所有企业摆脱同质化竞争。 真正拉开企业差距的,仍然是产品能否形成辨识度、渠道能否持续触达消费者,以及收入增长究竟来自价格推动,还是来自产品销量、品类扩张和品牌影响力的共同提升。 在金价高位运行、消费分层加剧的2026年上半年,西普尼
$西普尼(02583)$
的增长成色究竟如何?细读这份中报,三个关键信号,分别指向这家公司的现在与未来。 1 品牌引擎与产能效率带来的财务质变 财报数据显示,2026年上半年,西普尼录得收入约人民币3.33亿元,同比增长15.9%;毛利约人民币1.39亿元,同比大增54.2%,毛利率从31.2%跃升至41.6%,期内溢利约人民币9910万元,同比增长75.3%,每股基本盈利1.69元。剔除上市开支影响后,经调整期内溢利同比增长62.9%。更值得关注的是,董事会建议派发每股人民币0.5元的中期股息,派息率约30%。 收入结构方面,按产品拆分,手表收入约2.37亿元,同比增长约58%,占收入比重从52.1%大幅提升至71.0%,高单价、高附加值的手表依旧是绝对主力。 再按业务模式拆分,自有品牌(OBM)与代工(ODM)并举的双轮驱动格局未变,但本期自有品牌增长更为显著:OBM收入约2.49亿元,同比增长64.1%,占比升至74.7%。放量背后的动力清晰可循。 一方面来自线下渠道。西普尼经销为主、直销为辅的体系覆盖全国超3000个线下零售点,本期手表线下经销收入约2.14亿元,同比增长约51.7%,渠道密度转化为渠道动销,经销底盘持续放量。 另一方面,随着电子商务
看
419
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
净利大增75%+上市以来首次派息,西普尼 (02583.HK) 中报含金量几何?
港股多模态
港股多模态
·
08-27
一图读懂:神威药业(02877.HK)2026年度中期业绩
一图读懂:神威药业(02877.HK)2026 年度中期业绩
$神威药业(02877)$
$恒生指数(HSI)$
看
775
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:神威药业(02877.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-26
一图读懂:来凯医药(02105.HK)2026年度中期业绩
$来凯医药-B(02105)$
授权收入落地,亏损大幅收窄。收益1.5亿元来自LAE118及LAE002对外授权交易,毛利率86.1%,期内亏损收窄98.03%;现金及银行结余与定期存款合计约11.22亿元。
看
498
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:来凯医药(02105.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-26
一图读懂:轩竹生物(02575.HK)2026年度中期业绩
$轩竹生物-B(02575)$
商业化放量,亏损持续收窄。收入0.69亿元(+288.1%),期内亏损收窄32.1%,经营开支同比-22.2%;在手现金5.08亿元,对外授权实现中东北非市场突破。
看
536
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:轩竹生物(02575.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-25
一图读懂:国药控股(01099.HK)2026年度中期业绩
$国药控股(01099)$
$恒生指数(HSI)$
一图读懂:国药控股(01099.HK)2026年度中期业绩
看
1,461
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:国药控股(01099.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-24
一图读懂:紫金矿业(02899.HK)2026年度中期业绩
一图读懂:紫金矿业(02899.HK)2026年度中期业绩
$紫金矿业(02899)$
$恒生指数(HSI)$
看
966
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:紫金矿业(02899.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-24
一图读懂:艾美疫苗(06660.HK)2026年度中期业绩
$艾美疫苗(06660)$
$恒生指数(HSI)$
一图读懂:艾美疫苗(06660.HK)2026年度中期业绩
看
594
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:艾美疫苗(06660.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-24
一图读懂:蓝思科技(06613.HK)2026年度中期业绩
一图读懂:蓝思科技(06613.HK)2026年度中期业绩
$蓝思科技(06613)$
$恒生指数(HSI)$
看
1,039
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:蓝思科技(06613.HK)2026年度中期业绩
港股多模态
港股多模态
·
08-24
一图读懂:中国电信(00728.HK)2026年度中期业绩
$中国电信(00728)$
$恒生指数(HSI)$
一图读懂:中国电信(00728.HK)2026年度中期业绩
看
1,053
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
一图读懂:中国电信(00728.HK)2026年度中期业绩
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4247382024214830","uuid":"4247382024214830","gmtCreate":1784278804167,"gmtModify":1785484862213,"name":"港股多模态","pinyin":"ggdmtgangguduomotai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":0,"tweetSize":43,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":605105091989720,"gmtCreate":1788767786668,"gmtModify":1788767792667,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"中国水发(00750.HK)估值严重被低估,2025年及2026年中期扭亏为盈","htmlText":"<a href=\"https://laohu8.com/S/00750\">$水发兴业能源(00750)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 数据来源:真灼财经综合公司年报、2026年中期业绩公告及情景模型测算制图","listText":"<a href=\"https://laohu8.com/S/00750\">$水发兴业能源(00750)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 数据来源:真灼财经综合公司年报、2026年中期业绩公告及情景模型测算制图","text":"$水发兴业能源(00750)$ $恒生指数(HSI)$ 数据来源:真灼财经综合公司年报、2026年中期业绩公告及情景模型测算制图","images":[{"img":"https://static.tigerbbs.com/9e4f1e66453976b4c951f9302e1f7887","width":"1210","height":"1570"},{"img":"https://static.tigerbbs.com/b0c643c10fd905681ffaf241b1243e56","width":"1242","height":"1451"},{"img":"https://static.tigerbbs.com/6dc7daa7b567c837e6c62d10774de1f1","width":"1182","height":"1564"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605105091989720","isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"CN","totalScore":0},{"id":602540661666280,"gmtCreate":1788141685644,"gmtModify":1788144017082,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"净利大增75%+上市以来首次派息,西普尼 (02583.HK) 中报含金量几何?","htmlText":"黄金消费行业从来不缺热度,但对一家企业而言,金价上涨、市场关注度提升,并不必然转化为经营质量的改善。原材料价格上行可能推高产品售价,也可能抑制终端需求;消费者对黄金的关注度提升,可以带动行业景气,却未必能够帮助所有企业摆脱同质化竞争。 真正拉开企业差距的,仍然是产品能否形成辨识度、渠道能否持续触达消费者,以及收入增长究竟来自价格推动,还是来自产品销量、品类扩张和品牌影响力的共同提升。 在金价高位运行、消费分层加剧的2026年上半年,西普尼 <a href=\"https://laohu8.com/S/02583\">$西普尼(02583)$</a> 的增长成色究竟如何?细读这份中报,三个关键信号,分别指向这家公司的现在与未来。 1 品牌引擎与产能效率带来的财务质变 财报数据显示,2026年上半年,西普尼录得收入约人民币3.33亿元,同比增长15.9%;毛利约人民币1.39亿元,同比大增54.2%,毛利率从31.2%跃升至41.6%,期内溢利约人民币9910万元,同比增长75.3%,每股基本盈利1.69元。剔除上市开支影响后,经调整期内溢利同比增长62.9%。更值得关注的是,董事会建议派发每股人民币0.5元的中期股息,派息率约30%。 收入结构方面,按产品拆分,手表收入约2.37亿元,同比增长约58%,占收入比重从52.1%大幅提升至71.0%,高单价、高附加值的手表依旧是绝对主力。 再按业务模式拆分,自有品牌(OBM)与代工(ODM)并举的双轮驱动格局未变,但本期自有品牌增长更为显著:OBM收入约2.49亿元,同比增长64.1%,占比升至74.7%。放量背后的动力清晰可循。 一方面来自线下渠道。西普尼经销为主、直销为辅的体系覆盖全国超3000个线下零售点,本期手表线下经销收入约2.14亿元,同比增长约51.7%,渠道密度转化为渠道动销,经销底盘持续放量。 另一方面,随着电子商务","listText":"黄金消费行业从来不缺热度,但对一家企业而言,金价上涨、市场关注度提升,并不必然转化为经营质量的改善。原材料价格上行可能推高产品售价,也可能抑制终端需求;消费者对黄金的关注度提升,可以带动行业景气,却未必能够帮助所有企业摆脱同质化竞争。 真正拉开企业差距的,仍然是产品能否形成辨识度、渠道能否持续触达消费者,以及收入增长究竟来自价格推动,还是来自产品销量、品类扩张和品牌影响力的共同提升。 在金价高位运行、消费分层加剧的2026年上半年,西普尼 <a href=\"https://laohu8.com/S/02583\">$西普尼(02583)$</a> 的增长成色究竟如何?细读这份中报,三个关键信号,分别指向这家公司的现在与未来。 1 品牌引擎与产能效率带来的财务质变 财报数据显示,2026年上半年,西普尼录得收入约人民币3.33亿元,同比增长15.9%;毛利约人民币1.39亿元,同比大增54.2%,毛利率从31.2%跃升至41.6%,期内溢利约人民币9910万元,同比增长75.3%,每股基本盈利1.69元。剔除上市开支影响后,经调整期内溢利同比增长62.9%。更值得关注的是,董事会建议派发每股人民币0.5元的中期股息,派息率约30%。 收入结构方面,按产品拆分,手表收入约2.37亿元,同比增长约58%,占收入比重从52.1%大幅提升至71.0%,高单价、高附加值的手表依旧是绝对主力。 再按业务模式拆分,自有品牌(OBM)与代工(ODM)并举的双轮驱动格局未变,但本期自有品牌增长更为显著:OBM收入约2.49亿元,同比增长64.1%,占比升至74.7%。放量背后的动力清晰可循。 一方面来自线下渠道。西普尼经销为主、直销为辅的体系覆盖全国超3000个线下零售点,本期手表线下经销收入约2.14亿元,同比增长约51.7%,渠道密度转化为渠道动销,经销底盘持续放量。 另一方面,随着电子商务","text":"黄金消费行业从来不缺热度,但对一家企业而言,金价上涨、市场关注度提升,并不必然转化为经营质量的改善。原材料价格上行可能推高产品售价,也可能抑制终端需求;消费者对黄金的关注度提升,可以带动行业景气,却未必能够帮助所有企业摆脱同质化竞争。 真正拉开企业差距的,仍然是产品能否形成辨识度、渠道能否持续触达消费者,以及收入增长究竟来自价格推动,还是来自产品销量、品类扩张和品牌影响力的共同提升。 在金价高位运行、消费分层加剧的2026年上半年,西普尼 $西普尼(02583)$ 的增长成色究竟如何?细读这份中报,三个关键信号,分别指向这家公司的现在与未来。 1 品牌引擎与产能效率带来的财务质变 财报数据显示,2026年上半年,西普尼录得收入约人民币3.33亿元,同比增长15.9%;毛利约人民币1.39亿元,同比大增54.2%,毛利率从31.2%跃升至41.6%,期内溢利约人民币9910万元,同比增长75.3%,每股基本盈利1.69元。剔除上市开支影响后,经调整期内溢利同比增长62.9%。更值得关注的是,董事会建议派发每股人民币0.5元的中期股息,派息率约30%。 收入结构方面,按产品拆分,手表收入约2.37亿元,同比增长约58%,占收入比重从52.1%大幅提升至71.0%,高单价、高附加值的手表依旧是绝对主力。 再按业务模式拆分,自有品牌(OBM)与代工(ODM)并举的双轮驱动格局未变,但本期自有品牌增长更为显著:OBM收入约2.49亿元,同比增长64.1%,占比升至74.7%。放量背后的动力清晰可循。 一方面来自线下渠道。西普尼经销为主、直销为辅的体系覆盖全国超3000个线下零售点,本期手表线下经销收入约2.14亿元,同比增长约51.7%,渠道密度转化为渠道动销,经销底盘持续放量。 另一方面,随着电子商务","images":[{"img":"https://static.tigerbbs.com/28d0a99ab3b451059959f262fc079788","width":"1561","height":"1007"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602540661666280","isVote":1,"tweetType":1,"viewCount":419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":601235949630416,"gmtCreate":1787823121982,"gmtModify":1787823128660,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:神威药业(02877.HK)2026年度中期业绩","htmlText":"一图读懂:神威药业(02877.HK)2026 年度中期业绩 <a href=\"https://laohu8.com/S/02877\">$神威药业(02877)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a>","listText":"一图读懂:神威药业(02877.HK)2026 年度中期业绩 <a href=\"https://laohu8.com/S/02877\">$神威药业(02877)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a>","text":"一图读懂:神威药业(02877.HK)2026 年度中期业绩 $神威药业(02877)$ $恒生指数(HSI)$","images":[{"img":"https://static.tigerbbs.com/a74680dbde7e678d5d0983b56c492519","width":"1280","height":"6201"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601235949630416","isVote":1,"tweetType":1,"viewCount":775,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600887507440104,"gmtCreate":1787738083538,"gmtModify":1787738091621,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:来凯医药(02105.HK)2026年度中期业绩","htmlText":"<a href=\"https://laohu8.com/S/02105\">$来凯医药-B(02105)$</a> 授权收入落地,亏损大幅收窄。收益1.5亿元来自LAE118及LAE002对外授权交易,毛利率86.1%,期内亏损收窄98.03%;现金及银行结余与定期存款合计约11.22亿元。","listText":"<a href=\"https://laohu8.com/S/02105\">$来凯医药-B(02105)$</a> 授权收入落地,亏损大幅收窄。收益1.5亿元来自LAE118及LAE002对外授权交易,毛利率86.1%,期内亏损收窄98.03%;现金及银行结余与定期存款合计约11.22亿元。","text":"$来凯医药-B(02105)$ 授权收入落地,亏损大幅收窄。收益1.5亿元来自LAE118及LAE002对外授权交易,毛利率86.1%,期内亏损收窄98.03%;现金及银行结余与定期存款合计约11.22亿元。","images":[{"img":"https://static.tigerbbs.com/cad3b5054b27249d89b5871ad4d45136","width":"1588","height":"7304"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600887507440104","isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600874921416040,"gmtCreate":1787735034043,"gmtModify":1787735041831,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:轩竹生物(02575.HK)2026年度中期业绩","htmlText":"<a href=\"https://laohu8.com/S/02575\">$轩竹生物-B(02575)$</a> 商业化放量,亏损持续收窄。收入0.69亿元(+288.1%),期内亏损收窄32.1%,经营开支同比-22.2%;在手现金5.08亿元,对外授权实现中东北非市场突破。","listText":"<a href=\"https://laohu8.com/S/02575\">$轩竹生物-B(02575)$</a> 商业化放量,亏损持续收窄。收入0.69亿元(+288.1%),期内亏损收窄32.1%,经营开支同比-22.2%;在手现金5.08亿元,对外授权实现中东北非市场突破。","text":"$轩竹生物-B(02575)$ 商业化放量,亏损持续收窄。收入0.69亿元(+288.1%),期内亏损收窄32.1%,经营开支同比-22.2%;在手现金5.08亿元,对外授权实现中东北非市场突破。","images":[{"img":"https://static.tigerbbs.com/6257ebbdb12b42e46b449580dbf38c2e","width":"1588","height":"7260"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600874921416040","isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600566449198064,"gmtCreate":1787648499188,"gmtModify":1787648512094,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:国药控股(01099.HK)2026年度中期业绩","htmlText":"<a href=\"https://laohu8.com/S/01099\">$国药控股(01099)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 一图读懂:国药控股(01099.HK)2026年度中期业绩","listText":"<a href=\"https://laohu8.com/S/01099\">$国药控股(01099)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 一图读懂:国药控股(01099.HK)2026年度中期业绩","text":"$国药控股(01099)$ $恒生指数(HSI)$ 一图读懂:国药控股(01099.HK)2026年度中期业绩","images":[{"img":"https://static.tigerbbs.com/ba12023a85df17ebd0b7b74703e2a870","width":"1280","height":"4339"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600566449198064","isVote":1,"tweetType":1,"viewCount":1461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600258801005352,"gmtCreate":1787573380895,"gmtModify":1787573389665,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:紫金矿业(02899.HK)2026年度中期业绩","htmlText":"一图读懂:紫金矿业(02899.HK)2026年度中期业绩 <a href=\"https://laohu8.com/S/02899\">$紫金矿业(02899)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a>","listText":"一图读懂:紫金矿业(02899.HK)2026年度中期业绩 <a href=\"https://laohu8.com/S/02899\">$紫金矿业(02899)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a>","text":"一图读懂:紫金矿业(02899.HK)2026年度中期业绩 $紫金矿业(02899)$ $恒生指数(HSI)$","images":[{"img":"https://static.tigerbbs.com/1fb12037c88a6700eee16877dafb957a","width":"1588","height":"9516"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600258801005352","isVote":1,"tweetType":1,"viewCount":966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600224645322168,"gmtCreate":1787565095898,"gmtModify":1787565103192,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:艾美疫苗(06660.HK)2026年度中期业绩","htmlText":"<a href=\"https://laohu8.com/S/06660\">$艾美疫苗(06660)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 一图读懂:艾美疫苗(06660.HK)2026年度中期业绩","listText":"<a href=\"https://laohu8.com/S/06660\">$艾美疫苗(06660)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 一图读懂:艾美疫苗(06660.HK)2026年度中期业绩","text":"$艾美疫苗(06660)$ $恒生指数(HSI)$ 一图读懂:艾美疫苗(06660.HK)2026年度中期业绩","images":[{"img":"https://static.tigerbbs.com/3feb78952afb2592b168aa140cacb9ea","width":"1280","height":"6789"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600224645322168","isVote":1,"tweetType":1,"viewCount":594,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600221897863208,"gmtCreate":1787563376853,"gmtModify":1787563464339,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:蓝思科技(06613.HK)2026年度中期业绩","htmlText":"一图读懂:蓝思科技(06613.HK)2026年度中期业绩 <a href=\"https://laohu8.com/S/06613\">$蓝思科技(06613)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a>","listText":"一图读懂:蓝思科技(06613.HK)2026年度中期业绩 <a href=\"https://laohu8.com/S/06613\">$蓝思科技(06613)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a>","text":"一图读懂:蓝思科技(06613.HK)2026年度中期业绩 $蓝思科技(06613)$ $恒生指数(HSI)$","images":[{"img":"https://static.tigerbbs.com/4e6630b41b035754c5889414fb0d0cbf","width":"1588","height":"8782"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600221897863208","isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600184471224704,"gmtCreate":1787555188557,"gmtModify":1787555201850,"author":{"id":"4247382024214830","authorId":"4247382024214830","name":"港股多模态","avatar":"https://static.tigerbbs.com/2298dd1de2ab65c9e32ecd74a05a9da5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247382024214830","idStr":"4247382024214830"},"themes":[],"title":"一图读懂:中国电信(00728.HK)2026年度中期业绩","htmlText":"<a href=\"https://laohu8.com/S/00728\">$中国电信(00728)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 一图读懂:中国电信(00728.HK)2026年度中期业绩","listText":"<a href=\"https://laohu8.com/S/00728\">$中国电信(00728)$</a> <a href=\"https://laohu8.com/S/HSI\">$恒生指数(HSI)$</a> 一图读懂:中国电信(00728.HK)2026年度中期业绩","text":"$中国电信(00728)$ $恒生指数(HSI)$ 一图读懂:中国电信(00728.HK)2026年度中期业绩","images":[{"img":"https://static.tigerbbs.com/d0e2f94de694ef80376be00586ae1aa0","width":"1280","height":"4656"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600184471224704","isVote":1,"tweetType":1,"viewCount":1053,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}